First recurrent VTE or VTE-related death in specific subgroups. (A) For Hokusai-VTE, we used event data for the overall study period.3 The group of patients with impaired renal function includes 28 DOAC recipients and 32 VKA recipients with a creatinine clearance <30 mL per minute (protocol violations). Heterogeneity patients with an index PE I2 = 0%, P = .65; patients with an index DVT I2 = 0%, P = .41; patients with a body weight <100 kg I2 = 3%, P = .40; patients with a body weight ≥100 kg I2 = 0%, P = .71; patients with a creatinine clearance 30 to 49 mL per minute I2 = 0%, P = .61; patients with a creatinine clearance ≥50 mL per minute I2 = 0%, P = .59; patients <75 years of age I2 = 0%, P = .71; patients ≥75 years of age I2 = 0%, P = .95; patients without cancer I2 = 0%, P = .57; and patients with cancer I2 = 0%, P = .99. (B) Major bleeding in specific subgroups. For the subgroup analyses of patients >75 years of age and patients with a creatinine clearance of 30 to 49 mL per minute, we used the pooled RE-COVER data from the double-dummy period only. For Hokusai-VTE, we used event data for the overall study period.3 The group of patients with impaired renal function includes 28 DOAC recipients and 32 VKA recipients with a creatinine clearance <30 mL per minute (protocol violations). Heterogeneity patients with a creatinine clearance 30 to 49 mL per minute I2 = 11%, P = .35; patients with a creatinine clearance ≥50 mL per minute I2 = 63%, P = .03; patients <75 years of I2 = 28%, P = .24; patients ≥75 years of age I2 = 60%, P = .04; patients without cancer I2 = 54%, P = .06; patients with cancer I2 = 0%, P = .73.
